# Compare MOTS-c and NAD+ — VitaPro Peptides > A side-by-side comparison of two Longevity & Cellular Health research compounds — MOTS-c and NAD+ — across molecule class, evidence base, administration studied, regulatory status and key cautions. Where MOTS-c and NAD+ converge, where they diverge, and — most importantly — how far the evidence behind each one actually reaches. ## The short version This page lines up [MOTS-c](/mots-c) and [NAD+](/nad) on the dimensions that matter most when reading longevity research: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline is simple: NAD+ has human randomized controlled trial data showing that precursors raise blood NAD+ and produce some functional improvements; MOTS-c has compelling animal and mechanistic data but no human efficacy trials at all. Both are connected to mitochondrial biology. Neither is presented here with a human dose. ## The comparison matrix | Dimension | MOTS-c | NAD+ | | --- | --- | --- | | Peptide class | Mitochondrially-encoded 16-amino-acid peptide (MDP) | Endogenous redox coenzyme / dinucleotide | | Most-studied in | Skeletal muscle metabolism, aging, physical performance | Energy metabolism, DNA repair, aging biology | | Evidence base (model) | Mostly mice and rats; human data are observational biomarker associations only [2][3] | In vitro + animal + multiple human RCTs (precursor supplementation) [8][9][10][12] | | Administration studied | Subcutaneous and IP injection in mice [4][6]; no validated human route | Oral (NMN, NR) in human RCTs; IV infusion in wellness settings [9][12] | | Regulatory / WADA status | Not approved (FDA); prohibited in elite sport (WADA) [1] | NAD+ and NMN/NR sold as dietary supplements (NMN status contested); IV compounded; not WADA-prohibited | | Key caution | No human efficacy trials; animal doses not extrapolatable [2] | Blood NAD+ rises in trials but hard clinical outcomes (longevity, disease) remain unproven in humans [8] | ## Molecule class MOTS-c and NAD+ are structurally distinct in every way. MOTS-c is a short peptide — 16 amino acids — translated from an open reading frame within mitochondrial ribosomal RNA. It is a *signaling molecule*: it responds to metabolic stress by activating AMPK and, under certain conditions, traveling to the nucleus to shift gene expression [5][6]. NAD+ is not a peptide at all — it is a dinucleotide, a small molecule built from two joined nucleotides, that functions as a *carrier* (picking up electrons in metabolism) and as a *consumed substrate* for signaling enzymes including sirtuins and PARPs [11]. The two molecules are related by context — both tie back to mitochondrial function and energy sensing — not by chemical family. ## Most-studied in MOTS-c research concentrates on skeletal muscle as the primary target: glucose uptake, insulin sensitivity, muscle atrophy prevention, and physical performance across different ages in mice [1][4][6]. NAD+ research is broader by nature, because the coenzyme is present in every cell. The human trial data tend to focus on metabolic function (muscle insulin sensitivity), physical function (walking distance), and blood NAD+ as a biomarker; animal work covers a wider range including cardiovascular, neurological, and longevity endpoints [9][10][11]. ## Evidence base (model) This is where the two clearly separate. NAD+ precursors have been tested in multiple human randomized controlled trials — including a multicenter, double-blind, placebo-controlled NMN trial showing dose-dependent blood NAD+ elevation and improved functional endpoints [9], and a controlled NR trial demonstrating dose-response pharmacology with no adverse effects [12]. MOTS-c, by contrast, has no completed human efficacy trials. The most direct human data are an observational cohort of 94 hemodialysis patients in which circulating MOTS-c independently predicted cardiovascular events and all-cause mortality [2] — an association study, not an intervention. A 2023 review consolidates the preclinical and translational picture [3]. ## Administration studied MOTS-c has been administered by subcutaneous and intraperitoneal injection in mouse studies; there is no validated human administration route, no human pharmacokinetic data, and no basis for extrapolating from rodent doses [4][6]. NAD+ precursors have been tested orally in humans in multiple trials; NMN at 300-900 mg/day and NR at 100-1000 mg/day both show dose-proportional blood NAD+ elevation with good tolerability [9][12]. IV NAD+ infusions are used in wellness settings but are backed by minimal controlled evidence and carry specific safety considerations including rapid plasma clearance and, for compounded products, a documented contamination risk. ## Regulatory / WADA status MOTS-c is not approved by the FDA for any human use and is prohibited in elite sport under WADA hormone-and-metabolic-modulator categories; athletes using it risk sanctions [1]. NAD+ is different: the coenzyme itself and its precursors NMN and NR are sold as dietary supplements in most markets, though the FDA has challenged NMN's supplement status on the grounds that it was investigated as a drug first. IV compounded NAD+ sits outside standard pharmaceutical approval and has been subject to a Class I recall for endotoxin contamination. Neither MOTS-c nor NAD+ (nor any precursor) appears on the WADA Prohibited List as a substance that directly maps to NAD+ supplementation. ## Key caution For MOTS-c the defining caveat is evidence stage: the entire efficacy case rests on animal studies and cell work, with human data limited to biomarker associations. There are no human dose-response data, no human pharmacokinetics, and the rodent doses used (0.5-15 mg/kg/day) are not translatable to people [2][3]. For NAD+ the caveat is different in character: human trials do exist and are generally reassuring on tolerability, but a 2025 *Nature Metabolism* review concluded that the evidence for hard clinical outcomes — preventing age-related disease, extending healthy life — remains limited and that tissue-specific NAD+ dynamics are poorly understood [8]. Raising blood NAD+ is proven; what that means for long-term health is not. Reading them together, the lesson is familiar: a promising mechanism does not guarantee a proven outcome. --- A literature digest tracing mitochondrial-linked longevity research — citations on record, never a product in hand.